drugset
drugset / Trial / NCT02706925

To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers

NCT02706925 ↗

Phase 1 Completed 63 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

To investigate safety, tolerability and pharmacokinetics, following single doses of BI 443651

Timeline

Start
2016-03-22
Primary completion
2016-06-12
Completion
2016-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 443651 Unknown — Inhaled

Indications

No indication recorded.